scholarly journals Correlation between glycated hemoglobin and venous blood sugar in diabetic patients monitored in Abidjan

2020 ◽  
Vol 14 (4) ◽  
pp. 135-141
Author(s):  
Aké Absalome MONDE ◽  
Massara CAMARA-CISSE ◽  
Konan Gervais KOFFI ◽  
Issiagha DIALLO ◽  
AKE Alexandre AKE ◽  
...  
2015 ◽  
Vol 133 (6) ◽  
pp. 460-464 ◽  
Author(s):  
Aurélie Affret ◽  
Luiz Henrique Maciel Griz ◽  
Eduarda Ângela Pessoa Cesse ◽  
Yuri da Silva Specht ◽  
Eduardo Maia Freese de Carvalho ◽  
...  

CONTEXT AND OBJECTIVE: To monitor glycemic control in diabetic patients, regular measurement of glycated hemoglobin (HbA1c) is recommended, but this can be difficult in remote places without access to laboratories. Portable point-of-care testing devices can prove a useful alternative. Our study aimed to assess the performance of one of them: A1CNow+, from Bayer. DESIGN AND SETTING: Cross-sectional accuracy study conducted at a university hospital in Brazil. METHODS: We made three successive measurements of capillary HbA1c using the A1CNow+ in 55 diabetic volunteers, while the same measurement was made on venous blood using the hospital reference method (Vitros 5,1 FS). We used the Bland-Altman graphical method to assess the A1CNow+ in relation to the Vitros 5,1 FS method. We also evaluated clinical usefulness by calculating the sensitivity and specificity of A1CNow+ for detecting patients with HbA1c lower than 7%, which is the usual limit for good glycemic control. RESULTS: The coefficient of variation between repeat testing for the A1CNow+ was 3.6%. The mean difference between A1CNow+ and Vitros 5,1 FS was +0.67% (95% confidence interval, CI: +0.52 to +0.81). The agreement limits of our Bland-Altman graph were -0.45 (95% CI: -0.71 to -0.19) and +1.82 (95% CI: +1.52 to +2.05). The sensitivity and specificity in relation to the 7% limit were respectively 100% and 67.7%. CONCLUSIONS: Although the A1CNow+ had good sensitivity, its accuracy was insufficient for use as a replacement for laboratory measurements of HbA1c, for glycemic control monitoring in diabetic patients.


2019 ◽  
Vol 4 (1) ◽  
pp. 660-665
Author(s):  
Rajneesh Jha ◽  
Amit Mishra ◽  
Meena Kumari Mishra ◽  
Ram Lala Mallick

Introduction: Thyroid hormones control growth, development and metabolic processes. Either excessive or deficient secretion of these hormones interfere with metabolism. Thyroid hormones, therefore, can alter a person's blood sugar. Relatively, thyroid peroxidise enzyme plays a key role in thyroid hormone production. The individuals who suffer from autoimmune thyroid diseases produce auto antibodies against thyroid peroxidise (called anti-TPO). Objectives: We aimed to investigate an association of anti-TPO titer among type-2 diabetic patients suffering from thyroid disorders attending the local hospital. Methodology: Based on findings of thyroid variables [such as total triiodothyronine (TT3 ), thyroxine (T4 ) and thyroid stimulated  hormone (TSH)], type-2 diabetic patients were categorized into Euthyroidism, Subclinical hypothyroidism and Hypothyroidism. In this hospital-based prospective study, venipuncture was performed to collect anti-cubital venous blood samples (n=100) from January to December, 2018. After separation of sera, estimation of certain parameters such as TT3, T4 , TSH and anti-TPO were carried out for correlative analyses. In this aspect, based on WHO guidelines, the patients who had fasting as well as postprandial blood sugar levels > 126 and 200 mg/dl were confirmed for diabetes mellitus. In addition, if these patients exhibited HbA1C levels > 10.8 %, they were enrolled into the 1 study. The patients who were hyperglycemic (with fasting as well as post-prandial blood sugar levels < 126 and 200 mg/dl) were excluded. Results: In the three groups as stated above, we observed that more a rise in level of glucose, greater were the values of TSH and anti-TPO. Conclusion Such findings emphasize and put an impact in situations of thyroid abnormality among type-2 local diabetic population.


2017 ◽  
Vol 4 (1) ◽  
pp. 225
Author(s):  
Irfan Ahamed H. B. ◽  
Bilal Bin Abdullah ◽  
Mohammed Ismail ◽  
Syed Aman Jagirdar

Background: The strongest relationship between insulin resistance and cardiovascular risk factors is observed in middle-aged persons rather than in older individuals. Hence it is important to evaluate the young high risk individuals for insulin resistance and to study its significant co-morbidities. Therefore, the present study was designed to evaluate the high risk individuals for insulin resistance and co-morbidities in young individuals.Methods: The body mass index and the waist-hip ratio of all the participants were measured. A 5 ml of fasting venous blood was collected from each patient and was used for the estimation of fasting blood glucose level, lipid profile, fasting insulin level and glycated hemoglobin using commercially available kit according to the manufacturer’s guidelines. Subjects’ full filling inclusion criteria and preliminary tests for insulin resistance are further evaluated with HOMA. The data obtained was represented as Mean±S.D and was analyzed for statistical significance using chi-square test and correlation of HOMA with study variables were performed using Pearson correlation test using SPSS Version 20. P - value less than 0.05 was considered the level of significance.Results: In the present study we found that, non- diabetic group patients are having strong association with hypertension and insulin resistance. When the study variables in the recruited subjects were correlated with HOMA using Pearson correlation, showed a significant correlation with fasting blood sugar, glycated hemoglobin and hypertension in diabetic patients. In non-diabetic subjects fasting blood sugar and glycated hemoglobin was not correlated significantly. But, hypertension showed a significant correlation.Conclusions: Insulin resistance was strongly associated with co-morbidities like hypertension, obesity,   hyperlipidemia, hyperuricemia. High incidence and prevalence of insulin resistance was also seen in non-diabetic individuals.


1987 ◽  
Vol 33 (12) ◽  
pp. 2153-2163 ◽  
Author(s):  
D A Armbruster

Abstract Glucose molecules are joined to protein molecules to form stable ketoamines, or fructosamines, through glycation, a nonenzymatic mechanism involving a labile Schiff base intermediate and the Amadori rearrangement. The amount of fructosamine in serum is increased in diabetes mellitus owing to the abnormally high concentration of sugar in blood. The concentration of fructosamine in serum thus reflects the degree of glycemic control attained by the diabetic patient and is useful in monitoring the effectiveness of therapy in diabetes over a period of several weeks, in a manner analogous to the determination of glycated hemoglobin. Of the analytical approaches used to measure fructosamine, affinity chromatography with m-aminophenylboronic acid and the nitroblue tetrazolium reduction method appear to be the most practical means for clinical chemists to assay fructosamine quickly, economically, and accurately. Fructosamine values can readily distinguish normal individuals and diabetic patients in good glycemic control from diabetics in poor control. Unlike glycated hemoglobin, which reflects the average blood sugar concentration over the past six to eight weeks, fructosamine reflects the average blood sugar concentration over the past two to three weeks. Thus a clinical advantage is that fructosamine responds more quickly to changes in therapy, thereby allowing for improved glycemic control. Used in conjunction with determinations of blood sugar and (or) of glycated hemoglobin, or by itself, the fructosamine assay can provide clinically useful information for the detection and control of diabetes.


1985 ◽  
Vol 54 (02) ◽  
pp. 413-414 ◽  
Author(s):  
Margarethe Geiger ◽  
Bernd R Binder

SummaryWe have demonstrated previously that fibrin enhanced plasmin formation by the vascular plasminogen activator was significantly impaired, when components isolated from the plasma of three uncontrolled diabetic patients (type I) were used to study plasminogen activation in vitro. In the present study it can be demonstrated that functional properties of the vascular plasminogen activators as well as of the plasminogens from the same three diabetic patients are significantly improved after normalization of blood sugar levels and improvement of HbAlc values. Most pronounced the Km of diabetic vascular plasminogen activator in the presence of fibrin returned to normal values, and for diabetic plasminogen the prolonged lag period until maximal plasmin formation occurred was shortened to almost control values. From these data we conclude that the observed abnormalities of in vitro fibrinolysis are not primarily associated with the diabetic disease, but might be secondary to metabolic disorders caused by diabetes.


Author(s):  
Shah Namrata Vinubhai ◽  
Pardeep Agarwal ◽  
Bushra Fiza ◽  
Ramkishan Jat

Background: Serum ferritin is known as an index for body iron stores also as an inflammatory marker and it is influenced by several disease. We were looking for a correlation between HbA1c and S. Ferritin in type 2 DM. Methodology: The present study a total of 150 participants were enrolled of which 100 were confirmed cases of Type 2 Diabetes Mellitus and rest 50 age and sex matched healthy subjects constituted the control group. All were screened for HbA1c, Fasting blood sugar, Post prandial blood sugar and S.Ferritin. Results: A highly significant variation and positive correlation was observed with respect to S.Ferritin and HbA1c levels. Mean S.Ferritin was high in the subgroup with poor glycemic control. Conclusion: The fasting, post prandial sugar levels, HbA1c and S.Ferritin were significantly higher in the diabetic subjects. This study shows a positive correlation between HbA1c and S. Ferritin levels. So we can conclude that in diabetic patients S. Ferritin may serve as an independent marker of poor glycemic and metabolic control. Keywords: Serum ferritin, Type 2 Diabetes Mellitus, HbA1c.


Antioxidants ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1056
Author(s):  
Simone Marconcini ◽  
Enrica Giammarinaro ◽  
Saverio Cosola ◽  
Giacomo Oldoini ◽  
Annamaria Genovesi ◽  
...  

Background: Periodontal infection may contribute to poor glycemic control and systemic inflammation in diabetic patients. The aim of the present study is to evaluate the efficacy of non-surgical periodontal treatment in diabetic patients by measuring oxidative stress outcomes. Methods: Sixty diabetic patients with periodontitis were enrolled, treated with scaling and full-mouth disinfection, and randomly prescribed chlorhexidine mouthwash, antioxidant mouthwash, or ozone therapy. Reactive oxygen metabolites (ROMs), periodontal parameters, and glycated hemoglobin were measured at baseline and then at 1, 3, and 6 months after. Results: At baseline, all patients presented with pathologic levels of plasmatic ROM (388 ± 21.36 U CARR), higher than the normal population. Probing depth, plaque index, and bleeding on probing values showed significant clinical improvements after treatment, accompanied by significant reductions of plasma ROM levels (p < 0.05). At the 6-month evaluation, the mean ROM relapsed to 332 ± 31.76 U CARR. Glycated hemoglobin decreased significantly (∆ = −0.52 units) after treatment. Both the test groups showed longer-lasting improvements of periodontal parameters. Conclusion: In diabetic patients, periodontal treatment was effective at reducing plasma ROM, which is an indicator of systemic oxidative stress and inflammation. The treatment of periodontal infection might facilitate glycemic control and decrease systemic inflammation.


Pharmacology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Vanessa Gonzalez-Covarrubias ◽  
Héctor Sánchez-Ibarra ◽  
Karla Lozano-Gonzalez ◽  
Sergio Villicaña ◽  
Tomas Texis ◽  
...  

<b><i>Introduction:</i></b> Genetic variants could aid in predicting antidiabetic drug response by associating them with markers of glucose control, such as glycated hemoglobin (HbA1c). However, pharmacogenetic implementation for antidiabetics is still under development, as the list of actionable markers is being populated and validated. This study explores potential associations between genetic variants and plasma levels of HbA1c in 100 patients under treatment with metformin. <b><i>Methods:</i></b> HbA1c was measured in a clinical chemistry analyzer (Roche), genotyping was performed in an Illumina-GSA array and data were analyzed using PLINK. Association and prediction models were developed using R and a 10-fold cross-validation approach. <b><i>Results:</i></b> We identified genetic variants on <i>SLC47A1, SLC28A1, ABCG2, TBC1D4,</i> and <i>ARID5B</i> that can explain up to 55% of the interindividual variability of HbA1c plasma levels in diabetic patients under treatment. Variants on <i>SLC47A1</i>, <i>SLC28A1</i>, and <i>ABCG2</i> likely impact the pharmacokinetics (PK) of metformin, while the role of the two latter can be related to insulin resistance and regulation of adipogenesis. <b><i>Conclusions:</i></b> Our results confirm previous genetic associations and point to previously unassociated gene variants for metformin PK and glucose control.


Sign in / Sign up

Export Citation Format

Share Document